Theralase Technologies Inc. (TLTFF) Q1 2025 Earnings Call Transcript
Theralase Technologies Inc. (OTCQX:TLTFF) Q1 2025 Earnings Conference Call June 9, 2025 11:00 AM ET Company Participants Kristina Hachey - CFO & Director Matthew Perraton - Corporate Participant Roger John Dumoulin-White - President, CEO & Director Matthew Perraton Good morning, everyone, and thank you for joining us today. I'm Matthew Perraton, Investor Relations Manager at Theralase Technologies, Inc., and it's a pleasure to welcome our shareholders and stakeholders to our first quarter 2025 Investor Conference Call.
Theralase Technologies Inc. (TLTFF) Q4 2024 Earnings Call Transcript
Theralase Technologies Inc. (OTCQX:TLTFF) Q4 2024 Earnings Conference Call March 19, 2025 11:00 AM ET Company Participants Matthew Perraton - Chairman of the Board Kristina Hachey - Chief Financial Officer Roger Dumoulin-White - President and Chief Executive Officer Conference Call Participants Matthew Perraton Good morning, everyone. My name is Matthew Perraton and I will be hosting Theralase Technologies Inc's Quarterly Investor Conference Call today.
Theralase Technologies Inc. (TLTFF) Q3 2024 Earnings Call Transcript
Theralase Technologies Inc. (OTCQX:TLTFF) Q3 2024 Earnings Conference Call December 4, 2024 11:00 AM ET Company Participants Matthew Perraton - Chairman of the Board Kristina Hachey - Chief Financial Officer Roger Dumoulin-White - President and Chief Executive Officer Conference Call Participants Matthew Perraton Good morning, everyone. My name is Matthew Perraton and I will be hosting Theralase Technologies Inc's Quarterly Investor Conference Call today.
Theralase continued to advance bladder cancer study during Q3
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) during the third quarter continued to make significant progress in its Study II clinical trial, which focuses on the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with a light-activated small molecule. The company reported that to date, 75 patients have been enrolled and treated, with the majority demonstrating promising outcomes.
Theralase Technologies completes private placement to support Phase 2 bladder cancer study
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that it has completed a non-brokered private placement, raising approximately $666,400 through the issuance of 2,221,334 units at $0.30 per unit. Each unit includes one common share and a warrant, allowing the purchase of an additional share at $0.45 within five years.
Theralase Technologies' bladder cancer treatment shows promising results in Phase 2 study - ICYMI
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) CEO Roger Dumoulin-White joined Proactive to discuss the latest developments for the company's lead drug, Ruvidar, which is targeting non-muscle invasive bladder cancer. Dumoulin-White shared updates from their ongoing Phase 2 registration study, in which Theralase's treatment is achieving impressive results, with three out of five patients becoming cancer-free after just one treatment session.
Theralase Technologies reports positive interim results from bladder cancer study
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) has provided an update on its ongoing bladder cancer clinical study involving Ruvidar, its light-activated drug, which is being investigated for Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). This Phase 2 trial, conducted in Canada and the US, is evaluating Ruvidar in combination with the TLC-3200 Medical Laser System.
Theralase Technologies announces closure of financing
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) has closed a non-brokered private placement, issuing 2.72 million units at $0.20 per unit, raising $544,000. Each unit includes one common share and one share purchase warrant with the warrants exercisable at $0.30 for five years.
Theraalse Technologies highlights Rudivar's superior efficacy in preclinical HSV-1 research
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) reported that its lead drug formulation Rudivar has been shown to be more effective than the currently approved standard of care drug Acyclovir in destroying Herpes Simplex Virus 1 (HSV-1) in a preclinical setting. The latest research carried out at the University of Manitoba demonstrated that Rudivar is more potent than Acyclovir, which does not cure herpes but can lessen the symptoms of the infection.
Theralase Technologies' Rutherrin shows promise against chemoresistance – ICYMI
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) CEO Roger Dumoulin-White talked with Proactive about the company's recent advancements in cancer treatment with its lead compound Rutherrin. Dumoulin-White discussed how Rutherrin is showing promise in overcoming chemoresistance when combined with the widely-used chemotherapy drug Cisplatin.
Theralase Technologies' Rutherrin shows promise in tacking chemoresistance in lung cancer
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that its lead drug formulation Rutherrin has been shown to provide a “significant” enhancement to the efficacy of cancer therapy Cisplatin in chemotherapy-resistant non-small cell lung cancer in a preclinical animal model. The company said that in a study using the Lewis Lung Cancer model, mice treated with a combination of Cisplatin and Rutherrin experienced a significantly higher survival rate compared to those treated with Cisplatin alone.
Theralase Technologies CEO discusses innovative cancer therapy Rutherrin – ICYMI
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) CEO Roger DuMoulin-White joined Proactive to discuss the latest advancements in the company's cancer treatment research. DuMoulin-White detailed the development of Rutherrin, an innovative drug designed to localize and destroy cancer cells in the body.
